October 25, 2010
GlaxoSmithKline (GSK) has licensed an anti-HIV integrase inhibitor discovered by the Shionogi Corporation in Japan. Because of these arrangements, this drug has the complex code name S/GSK1349572 and for now is increasingly referred to simply as '572 by researchers.
In lab experiments '572 has activity against HIV that is resistant to raltegravir, the only currently approved integrase inhibitor.
Researchers tested '572 in HIV-positive volunteers who had HIV that was resistant to raltegravir. Participants either substituted '572 in place of raltegravir or started taking '572 if they had already quit raltegravir. All participants had HIV that was also resistant to drugs from the three commonly used groups of anti-HIV medicines:
For the first 11 days of the study, participants received 50 mg once daily of '572 and no other drugs. After this period they also received an optimized background regimen based on resistance testing and medical history. This study is called Viking and so far only results from the first 11 days have been released.
The average profile of the 27 participants enrolled at the start of the study was as follows:
Examples of prior ART used included these drugs, which were used by the following proportion of participants:
That most of these potent drugs were commonly used suggests that the study group represented heavily pre-treated patients.
After 11 days, 21 out of 27 participants (78%) had their viral load fall to 400 copies/ml or less or had their viral load fall by 0.7 log.
Participants in this study had weak immune systems and sometimes it is difficult to separate drug side effects from symptoms of HIV disease in this population. Despite this, investigators determined that the following side effects were caused by '572:
Two participants had severely elevated levels of pancreatic enzymes; it is not yet certain if this is due to exposure to '572. However, no serious or life-threatening complications occurred after exposure to '572.
Long-term results from Viking are needed to assess the benefit of '572 in raltegravir-resistant people.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|